INFLIXIMAB EFFECT ON CLINICAL AND LABORATORY ACTIVITY PARAMETERS IN CASES OF VARIOUS JUVENILE ARTHRITIS VARIANTS

E.I. Alexeeva; A.M. Alekseeva; S.I. Valieva; T.M. Bzarova; R.V. Denisova

INFLIXIMAB EFFECT ON CLINICAL AND LABORATORY ACTIVITY PARAMETERS IN CASES OF VARIOUS JUVENILE ARTHRITIS VARIANTS

E.I. Alexeeva, A.M. Alekseeva, S.I. Valieva, T.M. Bzarova, R.V. Denisova

Abstract

The study analyses efficiency and safety of using mono clone antibodies for tumor necrosis factor (infliximab) for children with system (n = 21) and articular (n = 59) juvenile arthritis (JA). Infliksimab was injected intravenously (average dose of 6,8 ± 2,3 mg/kg/per injection) by a standard scheme (0, 2, 6, and each 8 following weeks). Together with antibcytokine therapy children still received immunity depressants (cyclosporine, methotraksat, leflunomid, peroral glucocorticoids). Research results prove that infliximab has pronounced hormone like anti-inflammatory effect after first injection for both patients with early and delayed articular JA variants. It reserved articular syndrome, reduced laboratory activity parameters, reduced degree of invalidity, improved quality of patients' lives. At the same time after three first infusions 88% of patients with system JA the effect was neutralized, articular syndrome activity increased, laboratory activity parameters increased, systematic indicators recurred. On the contrary, patients with both early and delayed JA variant the medication quickly and efficiently reduced activity of articular syndrome, personal estimations of pain levels and disease activity. Index of life quality was significantly improved, much like the selfbservice ability. Medication effect was registered after the first injection and remained over the whole period of observation (up to two years) in 61% cases of delayed and 93% of early articular ja variant. Thus, infliximab therapy is a reasonable, efficient and safe treatment of patients with both early and delyed articular JA.
Key words: juvenile arthritis, infliximab, treatment.

About the Authors

E.I. Alexeeva

Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation

A.M. Alekseeva

I.M. Sechenov Moscow Medical Academy
Russian Federation

S.I. Valieva

Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation

T.M. Bzarova

Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation

R.V. Denisova

Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation

References

1. Cush J.J. Rheumatoid arthritis. Clin. Symp. 1999; 51: 40.

2. Harris E.D. Rheumatoid arthritis: pathophysiology and implications for therapy. N. Engl. J. Med. 1990; 322: 1277–1289.

3. Edmonds J.P., Scott D.E., Furst D.E. et al. Antirheumatic drugs: aproposed new classification. Ibid. 1993; 36: 336–339.

4. Pincus T., Ferraccioli G., Sokka T. et al. Evidence from clinical trials and longBterm observational studies that disease modifying anti rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983. Rheumatology. 2002; 42: 1346–1356.

5. Алексеева Е.И., Шахбазян И.Е. Принципы патогенетической терапии тяжелых системных вариантов ювенильного ревматоидного артрита. М. 2002. C. 13.

6. Алексеева Е.И., Шахбазян И.Е. Критерии агрессивного течения ревматоидного артрита у детей. Терапевтический архив. 1998; 5: 37–41.

7. Woo P., Wedderburn L.R. Juvenile chronic arthritis. Lancet. 1998; 351: 969–973.

8. Woo P. The cytokine network in juvenile chronic arthritis. Rheum. Dis. Clin. North. Am. 1997; 23 (3): 491–498.

9. Sewell E., Trentham D. Pathogenesis of rheumatoid arthritis. Lancet . 1993; 341: 283–286.

10. Moore T.L. Immunopathogenes of juvenile rheumatoid arthritis. Curr. Opin. Rheumatol. 1999; 11: 377–383.

11. Firestein G.S. Pathogenesis of rheumatoid arthritis: how early is early? Arthritis Res Ther. 2005; 7 (4): 157–159.

12. Miossec P. The role of the Th1 and Th2 dichotomy in the pathogenesis of juvenile chronic arthritis. Rev. Rhum. 1997; 64 (10): 138–139.

13. Aarvak T., Chabaud M., Kallberg E., Miossec P., Natvig J.B. Change in the Th1/Th2 phenotype of memory T–cell clones from rheumatoid arthritis synovium. Scan. J. Immunol. 1999; 50: 1–9.

14. Mangge H., Kenzian H., Siegfried G. et al. Serum cytokines in juvenile rheumatoid arthritis. Arthritis &Rheumatism. 1995; 38: 211–220.

15. Feldman M., Brennan F., Maini R.N. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol. 1996; 14: 397–440.

16. Dinarello C.A., Moldawer L.L. Proinflammatory and antiinflammatory cytokines in rheumatoid arthritis. A primer for clinicians. Amgen Inc. 2000. P. 282.

17. Beutler B.A. The role of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (57): 16–21.

18. Brahn E., Peacock D., Banquero M., Lui D. Effects of tumor necrosis alpha (TNFB_) on collagen arthritis. Lymphokine Cytotine Res. 1992; 11: 253–256.

19. Nawroth P.P., Bank I., Handley D., Cassimerris J. et al. Tumor necrosis factor/cachectin interacts with endothelial cell receptor to induce release of interleukin 1. J. Exp. Med. 1986; 163: 1363–1375.

20. Haworth C., Brennan F.M., Chantry D., Turner M., Maini R.N., Feldmann M. Expression of granulocyte macrophage colony stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor. Eur. J. Immunol. 1999; 21: 2575–2579.

21. Mannel D.N., Echtenacher B. TNF in the inflammatory response. Chem. Immunol. 2000; 74: 141–161.

22. Tak P.P., Taylor P.C., Breedveld F.C, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor β monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis. Rheum. 1996; 39: 1077–1081.

23. Насонов Е.Л., Самсонов М.Ю., Тилз Г.П. и др. Растворимые молекулы адгезии (Р-селектин, ICAMB3) при ревматоидном артрите. Терапевтический архив. 1999; 5: 17–20.

24. Shingu M., Nagai Y., Isayama T., Naono T. et al. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin. Exp. Immunol. 1993; 94: 145–149.

25. Black R.A., Rauch C.T., Kozlosky C.J. et al. A metalloproteinase disintegrin that releases tumorBnecrosis factor β from cells. Nature. 1997; 385: 729–733.

26. Charles P., Elliot M.J., Davis D., et al. Regulation of cytokines, cytokine inhibitors, and acuteBphase proteins following anti TNF therapy in rheumatoid arthritis. J. Immunol. 1999; 163: 1521–1528.

27. Butler D.M., Maini R.N., Feldmann M., Brennan F.M. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparision of monoclonal anti TNF_ antibody with interleukin 1 receptor antagonist. Eur. Cytokine Netw. 1995; 6: 225–230.

28. Насонов Е.Л. Фактор некроза опухоли ᾳ — новая мишень для противовоспалительной терапии ревматоидного артрита. РМЖ. 2000; 17: 18–22.

29. Lipsky P.E., Desiree M.D., van der Heijde et al. Infliximab and Methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Medicine. 2000; 343: 1594–1601.

30. Elliot M.J., Maini R.N., Feldmann M. et al. Randomized double blind comparision of chimeric monoclonal antibody to tumor necrosis factor ᾳ (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994; 344: 1105–1110.

31. Maini R.N., Breedveld F.C., Kalden J.R. et al. Therapeutic efficacy of multiplay intravenous infusion of antiBtumor necrosis factor β monoclonal antibody combined with lowBdose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998; 41: 1552–1563.

32. Лукина Г.В. Антицитокиновая терапия ревматоидного артрита. Автореф. дис… докт. мед. наук. М. 2004.

33. Ruperto N., Lovell D.J., Cuttica R. et al. Randomized trial of infliximab (IFX) plus methotrexate (MTX) for the treatment of polyarticular juvenile rheumatoid arthritis (JRA). European League Against Rheumatism, June 8–11, 2005. Vienna, Austria. Poster SAT0325.

34. Vougiouka O., Rizou S., Grafakou O. Infliximab and etanercept in the treatment of juvenile idiopathic arthritis. The Athens experience. Ann. Rheum. Dis. 2001; 60: 176.

35. Lahdenne P., Vahasalo P., Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann. Rheum. Dis. 2003; 62: 245–247.

36. Scarazatti M., Beltramelli M., Dell'Era L. et al. Infliximab in juvenile idiopathic arthritis [abstract]. Ann. Rheum. Dis. 2001; 60: 180.

37. Vinje O., Obiora E., Forre O. Juvenile chronic polyarthritis treated with infliximab. Ann. Rheum. Dis. 2000; 59: 713–49. [Abstract 11.25].

38. Gerloni V., Pontikaki I., Gattinara M. et al. Efficacy of repeated intravenous infusions of an antiBTNFB_ monoclonal antibody (infliximab) in persistently active refractory juvenile idiopathic arthritis. Results of an open label prospective study. Arthritis Rheum. 2005; 52 (2): 548–553.

39. Chaturvedi V.P. Pilot study of chimeric monoclonal anti tumor necrosis factor alpha anti body (infliximab) with methotrexate in polyarticular juvenile idiopathic arthritis [abstract]. American College of Rheumatology 66th Annual Scientific Meeting, October 24–25, 2002. New Orleans, LA. Abstract LB12.

40. Honkanen V.E., Tynjala P., Vahasalo P., et al. Infliximab in juvenile arthritis: 1Byear followBup [abstract]. American College of Rheumatology 66th Annual Scientific Meeting, October 24–25, 2002. New Orleans, LA. Abstract 1272.

41. Honkanen V., Lappi M., Koskinen L. et al. Infliximab treatment in the refractory chronic uveitis of juvenile idiopathic arthritis (JIA) [abstract]. American College of Rheumatology 65th Annual Scientific Meeting, November 11–6, 2001. San Francisco, CA. Abstract 1438.

42. Masatlioglu S., Gogus F., Cevirgen D. et al. Infliximab in the treatment of refractory juvenile idiopathic arthritis. Arthritis Rheum. 2002; 46: 481.

43. Crandall W.V., Mackner L.M. Infusion reactions to infliximab in children and adolescents: frequency, outcome and predictive model. Aliment. Pharmacol. Ther. 2003; 17: 75–84.

44. Elliot M.J., Woo P., Charles P. et al. Suppression of fever and the acute phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumor necrosis factor β (cA2). Br. J. Rheumatol. 1997; 36: 589–593.

45. Billiau A.D., Cornillie F., Wouters C. Infliximab for systemic onset juvenile idiopathic arthritis: experience in 3 children. J. Rheumatol. 2002; 29: 1111–1114.

46. Kimura Y., Imundo L.F., Li S.C. High dose infliximab in the treatment of resistant systemic juvenile rheumatoid arthritis [abstract]. American College of Rheumatology 65th Annual Scientific Meeting, November 11–16, 2001. San Francisco, CA. Abstract 1316.

47. Foeldvari I., Kruger E., Schneider T. Acute, non obstructive, sterile chole cystitis associated with etanercept and infliximab for the treatment of juvenile polyarticular rheumatoid arthritis. Ann. Rheum. Dis. 2003; 62: 908–909.

48. Tutar E., Ekici F., Nacar N. et al. Delayed maculopapular, urticarial rash due to infliximab in two children with systemic onset juvenile idiopathic arthritis. Rheumatol. 2004; 43: 674–675.

49. Armbrust W., Kamphuis S.S., Wolfs T.W. et al. Tuberculosis in a nine year old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatol. 2004; 43: 527–529.

50. Mangge H., Heinzl B., Grubbauer HBM. et al. Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol. Int. 2003; 23: 258–261.

51. Алексеева Е.И., Алексеева А.М., Бзарова Т.М., и др. Эффективность лечения инфликсимабом резистентных форм ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2006; 2: 20–30.

52. Ruperto N., Lovell D.J., Cuttica R., Wilkinson N., Woo P. et al. A randomized, placeboB controlled trial of infliximab plus methotrexate for the treatment of polyarticularBcourse juvenile

53. rheumatoid arthritis. Arthritis Rheum. 2007; 56: 3096–3106.

54. Долгополова А., Бисярина В., Алексеев А. Вопросы ревматологии. 1979; 4: 3–7.

55. Arnet F.C., Edworthy S.M., Bloch D.A. et al. The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arthr. Rheum. 1988; 31: 315–324.

56. Чичасова Н.В., Насонова М.Б., Степанец О.В., Насонов Е.Л. Основные подходы к оценке активности ревматоидного артрита. Терапевтический архив. 2002; 5: 60–63.

57. Van der Heijde D.M.F.M., Van’t Hof M.A., Reil P.L.C.M. et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of disease activity score. Ann. Rheum. Dis. 1990; 49: 916–920.

Review

For citations:

Alexeeva E., Alekseeva A., Valieva S., Bzarova T., Denisova R. INFLIXIMAB EFFECT ON CLINICAL AND LABORATORY ACTIVITY PARAMETERS IN CASES OF VARIOUS JUVENILE ARTHRITIS VARIANTS. Current Pediatrics. 2008;7(2):42-54.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International.

ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Current Pediatrics

INFLIXIMAB EFFECT ON CLINICAL AND LABORATORY ACTIVITY PARAMETERS IN CASES OF VARIOUS JUVENILE ARTHRITIS VARIANTS

Abstract

About the Authors

References

Review

For citations:

Cookies policy